LOS
ANGELES, Nov. 6, 2023 /PRNewswire/ -- Aadi
Bioscience, Inc. (NASDAQ: AADI), a commercial-stage
biopharmaceutical company focused on developing and commercializing
precision therapies for genetically-defined cancers with
alterations in mTOR pathway genes, announced today participation in
the Jefferies London Healthcare Conference, taking
place November 14-16, 2023, in London. Dave Lennon,
Ph.D., President and CEO, will participate in a fireside chat
on Tuesday, November 14, 2023, at 8:30 am
GMT.
The fireside chat will be webcast live on the IR pages of
the Aadi Bioscience website and will be available
for replay for approximately 30 days following each investor
event.
About Aadi Bioscience, Inc.
Aadi is a commercial-stage biopharmaceutical company focused on
precision therapies for genetically defined cancers to bring
transformational therapies to cancer patients with mTOR pathway
driver alterations. Aadi received FDA approval and has
commercialized FYARRO® for the treatment of adult
patients with locally advanced unresectable or metastatic malignant
perivascular epithelioid cell tumor (PEComa).
Aadi has also initiated PRECISION1, a Phase 2 tumor-agnostic
registration-intended trial in mTOR inhibitor-naïve malignant solid
tumors
harboring TSC1 or TSC2 inactivating
alterations. More information on the Company's development pipeline
is available on the Aadi website at www.aadibio.com and
connect with us on Twitter and LinkedIn.
Contact:
Marcy
Graham
IR@aadibio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/aadi-bioscience-to-participate-in-jefferies-london-healthcare-conference-301978659.html
SOURCE Aadi Bioscience